Comparative Pharmacology
Head-to-head clinical analysis: DIDRONEL versus FOSAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIDRONEL versus FOSAMAX.
DIDRONEL vs FOSAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, reducing osteoclast activity and inducing osteoclast apoptosis.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
For Paget disease: 5 mg/kg orally once daily for 6 months, or 5 mg/kg orally once daily for 3 months if retreatment; for heterotopic ossification: 20 mg/kg orally once daily for 2 weeks pre- and 3 months post-surgery; for hypercalcemia of malignancy: 5-10 mg/kg orally once daily for up to 6 months.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
None Documented
None Documented
Terminal elimination half-life ranges from hours to weeks; initial phase 2-6 hours, deep bone phase up to several weeks due to slow release from bone.
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Renal: 50% unchanged; fecal/biliary: negligible; absorbed drug not excreted renally is retained in bone with slow release.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Category C
Category C
Bisphosphonate
Bisphosphonate